AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



(I)

wherein

W is [[N or]] CR_2;

R is halogen, CN, OCO_2R_9, CO_2R_{10}, $CONR_{11}R_{12}$, SO_xR_{13}, $NR_{14}R_{15}$, OR_{16}, COR_{17} or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, aryl or heteroaryl group each optionally substituted;

R_1 is an optionally substituted C_1-C_6alkyl, C_3-C_7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R_2 is H, halogen, or a C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_7cycloalkyl, aryl or heteroaryl group each optionally substituted;

R_3 and R_4 are each independently H or an optionally substituted C_1-C_6alkyl group;

R_5 is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_6 is a C_1-C_6alkyl, C_3-C_7cycloalkyl, C_2-C_6alkenyl or C_2-C_6alkynyl group each optionally substituted;

R_7 and R_8 are each independently H or a C_1-C_6alkyl, C_3-C_7cycloalkyl, C_2-C_6alkenyl or C_2-C_6alkynyl group each optionally substituted;

m, n and p are each independently 0 or an integer of 1, 2 or 3;

q and x are each independently 0 or an integer of 1 or 2;

R_9, R_{10}, R_{13} and R_{17} are each independently H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_{11} and R_{12} are each independently H or an optionally C_1-C_6alkyl group or R_{11} and R_{12} may be taken together with the atom to which they are attached to form a 5- to 7-member ring optionally containing another heteroatom selected from O, N or S;

R_{14} and R_{15} are each independently H or an optionally substituted C_1-C_4alkyl group or R_{14} and R_{15} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR_{18} or SO_x;

R_{16} is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and

R_{18} is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

2. (Original) The compound according to claim 1 wherein n is 0.

3. (Original) The compound according to claim 1 wherein R_5 is H.

4. (Original) The compound according to claim 1 wherein R_1 is an optionally substituted phenyl group.

5. (Original) The compound according to claim 2 wherein q is 0 or 1.

6. (Original) The compound according to claim 2 wherein m is 0 and p is 0.

7. (Original) The compound according to claim 5 wherein the piperidinyl or pyrrolidinyl group is attached in the 3-position.

8. (Original) The compound according to claim 6 wherein R_1 is an optionally substituted phenyl group and q is 0 or 1.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I



(I)

wherein

W is [[N or]] CR_2;

R is halogen, CN, OCO_2R_9, CO_2R_{10}, $CONR_{11}R_{12}$, SO_xR_{13}, $NR_{14}R_{15}$, OR_{16}, COR_{17} or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, aryl or heteroaryl group each optionally substituted;

R_1 is an optionally substituted C_1-C_6alkyl, C_3-C_7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R_2 is H, halogen, or a C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_7cycloalkyl, aryl or heteroaryl group each optionally substituted;

R_3 and R_4 are each independently H or an optionally substituted C_1-C_6alkyl group;

R_5 is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_6 is a C_1-C_6alkyl, C_3-C_7cycloalkyl, C_2-C_6alkenyl or C_2-C_6alkynyl group each optionally substituted;

R_7 and R_8 are each independently H or a C_1-C_6alkyl, C_3-C_7cycloalkyl, C_2-C_6alkenyl or C_2-C_6alkynyl group each optionally substituted;

m, n and p are each independently 0 or an integer of 1, 2 or 3;

q and x are each independently 0 or an integer of 1 or 2;

R_9, R_{10}, R_{13} and R_{17} are each independently H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_{11} and R_{12} are each independently H or an optionally C_1-C_6alkyl group or R_{11} and R_{12} may be taken together with the atom to which they are attached to form a 5- to 7-member ring optionally containing another heteroatom selected from O, N or S;

R_{14} and R_{15} are each independently H or an optionally substituted C_1-C_4alkyl group or R_{14} and R_{15} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR_{18} or SO_x;

R_{16} is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and

R_{18} is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

16. (Original) The composition according to claim 15 having a formula I compound wherein n is 0.

17. (Original) The composition according to claim 16 having a formula I compound wherein R_5 is H and q is 0 or 1.

18. (Original) The composition according to claim 17 having a formula I compound wherein R_1 is an optionally substituted phenyl group.

19. (Original) The composition according to claim 18 having a formula I compound wherein the piperidinyl or pyrrolidinyl group is attached in the 3-position.

20. (Currently Amended) A process for the preparation of a compound of formula I



(I)

wherein

W is [[N or]] CR_2;

R is halogen, CN, OCO_2R_9, CO_2R_{10}, $CONR_{11}R_{12}$, SO_xR_{13}, $NR_{14}R_{15}$, OR_{16}, COR_{17} or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, aryl or heteroaryl group each optionally substituted;

R_1 is an optionally substituted C_1-C_6alkyl, C_3-C_7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R_2 is H, halogen, or a C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_7cycloalkyl, aryl or heteroaryl group each optionally substituted;

R_3 and R_4 are each independently H or an optionally substituted C_1-C_6alkyl group;

R_5 is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_6 is a C_1-C_6alkyl, C_3-C_7cycloalkyl, C_2-C_6alkenyl or C_2-C_6alkynyl group each optionally substituted;

R_7 and R_8 are each independently H or a C_1-C_6alkyl, C_3-C_7cycloalkyl, C_2-C_6alkenyl or C_2-C_6alkynyl group each optionally substituted;

m, n and p are each independently 0 or an integer of 1, 2 or 3;

q and x are each independently 0 or an integer of 1 or 2;

R_9, R_{10}, R_{13} and R_{17} are each independently H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_{11} and R_{12} are each independently H or an optionally C_1-C_6alkyl group or R_{11} and R_{12} may be taken together with the atom to which they are attached to form a 5- to 7-member ring optionally containing another heteroatom selected from O, N or S;

R_{14} and R_{15} are each independently H or an optionally substituted C_1-C_4alkyl group or R_{14} and R_{15} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR_{18} or SO_x;

R_{16} is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and

R_{18} is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted

which process comprises reacting a compound of formula VIII



(VIII)

wherein W, R, R_1 and m are as described hereinabove with a protected azacyclic compound of formula IX



(IX)

wherein P is a protecting group; L is a leaving group; and R_3, R_4, R_6, R_7, R_8, n, p and q are as described hereinabove in the presence of a first base to give the protected formula I compound; and deprotecting said compound to give the free amine of formula I wherein R_5 is H optionally alkylating said amine with an alkylating agent,
R_5-L´, wherein L´ is a leaving group in the presence of a second base.